Corporate | 21 July 2008 15:48
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 18 July 2008: Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE 0005659700), a specialist in cancer diagnostic and treatment
products, has increased its role as a provider of radiation therapy
products in the Commonwealth of Independent States (CIS) via the
acquisition of several large-scale contracts. Commissioned by the Kazakh,
Ukrainian, and Russian governments as well as by the International Atomic
Energy Agency, headquartered in Vienna, Eckert & Ziegler's Berlin-based
subsidiary BEBIG GmbH will be supplying a dozen cancer clinics in
Kazakhstan, the Ukraine, Russia, and Armenia with the 'MultiSource' tumor
radiation systems before the end of this year. The contracts have a total
volume of well over 2 million EUR.
Dr. Edgar Löffler, Eckert & Ziegler AG's Executive Board member in charge
of the therapy segment explains that 'the installation of these systems
offers significant support for the fight against cancer in these regions.
The installations will additionally strengthen our market position in the
CIS, where the introduction of our innovative, cost-saving radiation
sources has been very well received, not only by specialists in the field,
but also by the international organizations that subsidize such systems. We
therefore anticipate that our 'MultiSource' high dose radiation system
(HDR) will continue to be highly esteemed by its buyers and users.'
HDR brachytherapy is a minimally invasive patient friendly, ambulant
radiation procedure whereby a miniature radiation source is placed inside
the body in very close proximity of the tumor. This reduces unnecessary
patient radiation exposure and leads to better treatment results.
About Eckert & Ziegler BEBIG GmbH
Eckert & Ziegler BEBIG GmbH has been manufacturing radiation therapy
products for more than sixteen years, and has in many countries acquired a
leading market position for tumor radiation systems. The company is also
Europe's leading producer of implants for the treatment of prostate cancer.
Eckert & Ziegler AG is an internationally active specialist for radioactive
applications in medicine, science, and industry. Listed on the Frankfurt
Prime Standard, the company posted sales of 54 million EUR in 2007, and
currently has approximately 430 employees.
The Executive Board
For more information, please contact:
Eckert & Ziegler AG
Thomas Scheuch, Investor Relations, Robert-Rössle-Str. 10, D-13125 Berlin
phone: +49 (0) 30 / 94 10 84-139; fax -112; e-mail: thomas.scheuch@ezag.de,
www.ezag.de
21.07.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------